Anne-Laure Morin , Emmanuelle Blanc , Armelle Phalipon , Pierre-Henri Bertoye , Philippe Amiel , Cécile Artaud , Philippe Barthélemy , Elisabeth Botelho-Nevers , Soizic Courcier , Jean-Luc Cracowski , François Eisinger , Remi Forrat , Alina Gruber , Euzebiusz Jamrozik , Odile Launay , Claire Le Jeunne , David Simhon
{"title":"控制性人体感染试验:法国实施的合法性和条件。","authors":"Anne-Laure Morin , Emmanuelle Blanc , Armelle Phalipon , Pierre-Henri Bertoye , Philippe Amiel , Cécile Artaud , Philippe Barthélemy , Elisabeth Botelho-Nevers , Soizic Courcier , Jean-Luc Cracowski , François Eisinger , Remi Forrat , Alina Gruber , Euzebiusz Jamrozik , Odile Launay , Claire Le Jeunne , David Simhon","doi":"10.1016/j.therap.2023.11.009","DOIUrl":null,"url":null,"abstract":"<div><p>This round table is the result of an observation. The observation being that controlled human infection clinical trials (also called “infectious challenge” trials or “Controlled Human Infection Models”, “CHIM”) recommended or even encouraged in the context of vaccine developments in particular, are not carried out in France. However, there are no formal prohibitions within regulations or ethical principles, which point to the prior assessment of risks and benefits for individuals and for society. The participants in this Round Table thus wished to examine, through the prism of their respective disciplines, the scientific and medical relevance of conducting such trials in France and, if possible, to imagine the conditions under which they would be carried out, thus resulting in recommendations on (1) the advisability of their conduct in France (2), the conditions under which they would be implemented in terms of logistics and regulations, and (3) their social acceptability. The recommendations on which the participants of the Round Table came to an agreement are presented as the analysis progresses.</p></div>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":"79 1","pages":"Pages 35-45"},"PeriodicalIF":2.2000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Controlled human infection trials: Legitimacy and conditions of implementation in France\",\"authors\":\"Anne-Laure Morin , Emmanuelle Blanc , Armelle Phalipon , Pierre-Henri Bertoye , Philippe Amiel , Cécile Artaud , Philippe Barthélemy , Elisabeth Botelho-Nevers , Soizic Courcier , Jean-Luc Cracowski , François Eisinger , Remi Forrat , Alina Gruber , Euzebiusz Jamrozik , Odile Launay , Claire Le Jeunne , David Simhon\",\"doi\":\"10.1016/j.therap.2023.11.009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>This round table is the result of an observation. The observation being that controlled human infection clinical trials (also called “infectious challenge” trials or “Controlled Human Infection Models”, “CHIM”) recommended or even encouraged in the context of vaccine developments in particular, are not carried out in France. However, there are no formal prohibitions within regulations or ethical principles, which point to the prior assessment of risks and benefits for individuals and for society. The participants in this Round Table thus wished to examine, through the prism of their respective disciplines, the scientific and medical relevance of conducting such trials in France and, if possible, to imagine the conditions under which they would be carried out, thus resulting in recommendations on (1) the advisability of their conduct in France (2), the conditions under which they would be implemented in terms of logistics and regulations, and (3) their social acceptability. The recommendations on which the participants of the Round Table came to an agreement are presented as the analysis progresses.</p></div>\",\"PeriodicalId\":23147,\"journal\":{\"name\":\"Therapie\",\"volume\":\"79 1\",\"pages\":\"Pages 35-45\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapie\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0040595723001920\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapie","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0040595723001920","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Controlled human infection trials: Legitimacy and conditions of implementation in France
This round table is the result of an observation. The observation being that controlled human infection clinical trials (also called “infectious challenge” trials or “Controlled Human Infection Models”, “CHIM”) recommended or even encouraged in the context of vaccine developments in particular, are not carried out in France. However, there are no formal prohibitions within regulations or ethical principles, which point to the prior assessment of risks and benefits for individuals and for society. The participants in this Round Table thus wished to examine, through the prism of their respective disciplines, the scientific and medical relevance of conducting such trials in France and, if possible, to imagine the conditions under which they would be carried out, thus resulting in recommendations on (1) the advisability of their conduct in France (2), the conditions under which they would be implemented in terms of logistics and regulations, and (3) their social acceptability. The recommendations on which the participants of the Round Table came to an agreement are presented as the analysis progresses.
期刊介绍:
Thérapie is a peer-reviewed journal devoted to Clinical Pharmacology, Therapeutics, Pharmacokinetics, Pharmacovigilance, Addictovigilance, Social Pharmacology, Pharmacoepidemiology, Pharmacoeconomics and Evidence-Based-Medicine. Thérapie publishes in French or in English original articles, general reviews, letters to the editor reporting original findings, correspondence relating to articles or letters published in the Journal, short articles, editorials on up-to-date topics, Pharmacovigilance or Addictovigilance reports that follow the French "guidelines" concerning good practice in pharmacovigilance publications. The journal also publishes thematic issues on topical subject.
The journal is indexed in the main international data bases and notably in: Biosis Previews/Biological Abstracts, Embase/Excerpta Medica, Medline/Index Medicus, Science Citation Index.